1. Home
  2. INDP vs FRSX Comparison

INDP vs FRSX Comparison

Compare INDP & FRSX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • INDP
  • FRSX
  • Stock Information
  • Founded
  • INDP 2000
  • FRSX N/A
  • Country
  • INDP United States
  • FRSX Israel
  • Employees
  • INDP N/A
  • FRSX N/A
  • Industry
  • INDP Biotechnology: Pharmaceutical Preparations
  • FRSX Computer Software: Prepackaged Software
  • Sector
  • INDP Health Care
  • FRSX Technology
  • Exchange
  • INDP Nasdaq
  • FRSX Nasdaq
  • Market Cap
  • INDP 6.0M
  • FRSX 7.0M
  • IPO Year
  • INDP N/A
  • FRSX 2017
  • Fundamental
  • Price
  • INDP $2.60
  • FRSX $2.43
  • Analyst Decision
  • INDP Strong Buy
  • FRSX
  • Analyst Count
  • INDP 2
  • FRSX 0
  • Target Price
  • INDP $238.00
  • FRSX N/A
  • AVG Volume (30 Days)
  • INDP 14.7K
  • FRSX 43.6K
  • Earning Date
  • INDP 08-13-2025
  • FRSX 09-21-2025
  • Dividend Yield
  • INDP N/A
  • FRSX N/A
  • EPS Growth
  • INDP N/A
  • FRSX N/A
  • EPS
  • INDP N/A
  • FRSX N/A
  • Revenue
  • INDP N/A
  • FRSX $452,000.00
  • Revenue This Year
  • INDP N/A
  • FRSX N/A
  • Revenue Next Year
  • INDP N/A
  • FRSX N/A
  • P/E Ratio
  • INDP N/A
  • FRSX N/A
  • Revenue Growth
  • INDP N/A
  • FRSX N/A
  • 52 Week Low
  • INDP $3.21
  • FRSX $2.17
  • 52 Week High
  • INDP $58.24
  • FRSX $18.41
  • Technical
  • Relative Strength Index (RSI)
  • INDP 18.83
  • FRSX 44.19
  • Support Level
  • INDP $6.26
  • FRSX $2.27
  • Resistance Level
  • INDP $6.65
  • FRSX $2.52
  • Average True Range (ATR)
  • INDP 0.76
  • FRSX 0.21
  • MACD
  • INDP -0.33
  • FRSX 0.03
  • Stochastic Oscillator
  • INDP 2.84
  • FRSX 47.04

About INDP Indaptus Therapeutics Inc.

Indaptus Therapeutics Inc is a pre-clinical biotechnology company engaged in developing a novel and patented systemically-administered anti-cancer and anti-viral immunotherapy. It has developed a proprietary platform that exploits bacteria's natural ability to activate both innate and adaptive cellular immune pathways. The company's clinical candidate Decoy20, has the ability to elicit single-agent activity and durable anti-tumor responses in the combination setting against colorectal, hepatocellular, pancreatic carcinoma, and non-Hodgkin's lymphoma models.

About FRSX Foresight Autonomous Holdings Ltd.

Foresight Autonomous Holdings Ltd is a technology company engaged in the design, development and commercialization of vision systems for the automotive industry. The company develops both in-line-of-sight vision systems and beyond-line-of-sight cellular-based applications through its wholly-owned subsidiaries. Its systems are designed to improve driving safety by enabling accurate and reliable threat detection while ensuring the lowest rates of false alerts. Foresight is pursuing several markets and believes its modern systems will revolutionize automotive safety by providing an automotive-grade, cost-effective platform.

Share on Social Networks: